Hoang V. Le

2016–Present:  Assistant Professor of Medicinal Chemistry, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi

2016–Present:  Research Assistant Professor, Research Institute of Pharmaceutical Sciences
School of Pharmacy, University of Mississippi

​2020–Present:  Member, UMMC Cancer Center and Research Institute

2019–2021:  Graduate Program Coordinator, Medicinal Chemistry Division, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi

2018–2019:  Visiting Scientist, St. Jude Children's Research Hospital

Postdoctoral Researcher, Northwestern University (2013 - 2016). Advisor: Richard Silverman

Ph.D., Cornell University, 2013. Advisor: Bruce Ganem

B.S., University of California, Berkeley, 2008. Advisor: Kenneth Raymond

2021:  P2 Teaching Team of the Year Award (Team Member), UM School of Pharmacy

2020:  P1 Teaching Team of the Year Award (Team Leader), UM School of Pharmacy

2018:  New Investigator Award, American Association of Colleges of Pharmacy (AACP)

​2010–2012:   NIH Chemistry/Biology Interface Training Grant

Co-inventor of OV329, licensed to OVID Therapeutics 2016-Present 

10/2011­–11/2011:  ​Avila Therapeutics, Inc. (now part of Bristol Myers Squibb)

2021–2022:  Topic Editor, "Targeting Cancer Metabolic Reprogramming for Cancer Therapy", Frontiers in Drug Discovery 

2021–Present:  Associate Editor, Frontiers in Drug Discovery 

2022:  Reviewer, NSF Graduate Research Fellowships Program (GRFP)

2021:  Reviewer, NSF SBIR/STTR program

2021:  Reviewer, NSF Graduate Research Fellowships Program (GRFP)

​2020:  Reviewer, NSF Graduate Research Fellowships Program (GRFP)

2019:  Reviewer, NSF Graduate Research Fellowships Program (GRFP)

2018:  Reviewer, Innovational Research Incentive Scheme – Veni Programme

2017:  Reviewer, NIH Macromolecular Structure and Function A Study Section

2017:  NIH Early Career Reviewer Program

2022:  ACS Leadership Institute

2022:  Member, AACP Chemistry Section Awards Committee 

2021–2022:  Chair-Elect, American Chemical Society Local Section, University of Mississippi 

2021–2022:  Vice Chair, Research and Graduate Affairs Committee, School of Pharmacy, University of Mississippi 

2021–Present:  Member, UM Mentoring Working Group 

2021–Present:  Member, UM Graduate School's Graduate Student Mental Health and Well-being Advisory Board

2021:  Member, AACP Chemistry Section Awards Committee

2018–2021:  Secretary (elected in 2018; re-elected in 2019 and 2020), American Chemical Society Local Section, University of Mississippi

​2020–2021:  Vice Chair, Research and Graduate Affairs Committee, School of Pharmacy, University of Mississippi

2019–Present:  Faculty Advisor, Ole Miss Vietnamese American Student Association (Ole VASA) 

2019–2020:  Member, AACP New Investigator Awards Review Committee

2019–2020:  Vice Chair, Research and Graduate Affairs Committee, School of Pharmacy, University of Mississippi

2017–2021:  Founder and Director, Science, Technology, Engineering and Math Summer Research Experience for Undergraduates (STEMS REU) Program, University of Mississippi

2016–2019:  Member, Research and Graduate Affairs Committee, School of Pharmacy, University of Mississippi

2022:  Poster Judge, MALTO Medicinal Chemistry and Pharmacognosy Meeting-in-Miniature

2022:  Poster Abstract Reviewer, 2022 AACP Annual Meeting

2022:  National Research Mentoring Network (NRMN)'s Grant Writing Coaching Program    

2021:  Poster Abstract Reviewer, Virtual Pharmacy Education: The 2021 AACP Annual Meeting

2021:  Judge, Regional Science Fair for Elementary Schools

2018:  NIGMS Mentoring Workshop for New Faculty in Organic and Biological Chemistry

2018:  NSF Chemistry Early Career Investigator Workshop

2018:  Poster Judge, MALTO Medicinal Chemistry and Pharmacognosy Meeting-in-Miniature

2018–Present:  Member, Experimental Therapeutics Group, UMMC Cancer Center and Research Institute

2018:  Poster Judge, Southeastern Undergraduate Research Conference (SURC)

2017:  Poster Judge, MALTO Medicinal Chemistry and Pharmacognosy Meeting-in-Miniature

2015:  NIH Training in Neurotherapeutics Discovery and Development for Academic Scientists

The Rho Chi Society (the Academic Honor Society in Pharmacy)

American Association of Colleges of Pharmacy

American Chemical Society (Divisions of Medicinal Chemistry and Organic Chemistry)

University of Mississippi

13)  Le, H. V.; Hossain, M. I. U.S. Patent Application 17,597,550 (filed January 11, 2022). L-γ-methyleneglutamine compounds and methods of use

Northwestern University

12)  Silverman, R. B.; Takaya, K.; Le, H. V.; Juncosa, J. I. India Patent IN 372532 (July 23, 2021). (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction, and hepatocellular carcinoma

11)  Silverman, R. B.; Takaya, K.; Le, H. V.; Juncosa, J. I. Australia Patent AU 2016334396 (July 22, 2021). (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction, and hepatocellular carcinoma 

10)  Silverman, R. B.; Juncosa, J.; Le, H. V.; Takaya, K. Israel Patent IL 258516 (April 1, 2021). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, a highly potent GABA aminotransferase inactivator for the treatment of epilepsy, addiction, and hepatocellular carcinoma 

9)  Silverman, R. B.; Juncosa, J.; Le, H. V.; Takaya, K. Japan Patent JP 6841821 (February 22, 2021). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction, and hepatocellular carcinoma 

8)  Silverman, R. B.; Juncosa, J.; Le, H. V.; Takaya, K. China Patent ZL 2016800590699 (February 12, 2021). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, a highly potent GABA aminotransferase inactivator for the treatment of epilepsy, addiction, and hepatocellular carcinoma 

7)  Silverman, R. B.; Le, H. V.; Hawker, D. D. U.S. Patent 10,800,753 B2 (October 13, 2020). Tetrahydrothiophene-based GABA aminotransferase inactivators and analogs thereof for treating neurological disorders 

6)  Silverman, R. B.; Le, H. V.; McLeod, R. L.; Hawker, D. D. U.S. Patent 10,632,088 B2 (April 28, 2020). Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria 

5)  Juncosa, J.; Le, H. V.; Silverman, R. B.; Takaya, K., Columbia Patent Certificado Numero 37025 (April 17, 2020). Compuestos derivados del ácido (S)-3-amino-4-(difluorometilenil)ciclopent-1-eno-1-carboxílico como inhibidores de GABA aminotransferase 

4)  Silverman, R. B.; Le, H. V.; Hawker, D. D. U.S. Patent 10,189,807 B2 (January 29, 2019). Tetrahydrothiophene-based GABA aminotransferase inactivators 

3)  Silverman, R. B.; Takaya, K.; Le, H. V.; Juncosa, J. I. U.S. Patent 9,993,449 B2 (June 12, 2018). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction, and hepatocellular carcinoma 

2)  Silverman, R. B.; Hawker, D. D.; Le, H. V. U.S. Patent 9,856,231 B2 (January 2, 2018). Tetrahydrothiophene-based GABA aminotransferase inactivators 

1)  Silverman, R. B.; Takaya, K.; Le, H. V.; Juncosa, J. I. U.S. Patent 9,670,141 B2 (June 6, 2017). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction, and hepatocellular carcinoma